News Conference News EAS 2023 High LDL, Poor Treatment, Early Death: HoFH Registry Paints Grim Picture Michael O'Riordan May 23, 2023
News Features Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD? Michael O'Riordan August 15, 2022
News Conference News EAS 2022 FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses Michael O'Riordan May 26, 2022
News Conference News EAS 2022 ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News EAS 2022 Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering Michael O'Riordan May 24, 2022
News Daily News Homozygous FH Diagnosis Often Comes Late, With Lackluster Care Michael O'Riordan February 10, 2022
News Features Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path Michael O'Riordan January 17, 2022
News Daily News British Medical Groups Express Concern About Inclisiran Rollout Michael O'Riordan December 14, 2021
News Features Hopes High for Anti-inflammatories to Combat COVID-19 Immune System Storms Caitlin E. Cox April 23, 2020
News Daily News Recurrent Events Common Among Young Patients With CAD Michael O'Riordan October 11, 2019
News Conference News SCCT 2019 Time to Ease Up on Prior Authorization for PCSK9 Inhibitors? Yael L. Maxwell July 15, 2019
News Daily News Price Chop for Evolocumab: PCSK9 Inhibitor Cost Cut by 60% Michael O'Riordan October 25, 2018